Compare FBDT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBDT | LSTA |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 28.9M |
| IPO Year | 2026 | 2000 |
| Metric | FBDT | LSTA |
|---|---|---|
| Price | $0.89 | $1.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 6.5M | 683.9K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.61 | $0.99 |
| 52 Week High | $1.25 | $5.07 |
| Indicator | FBDT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 50.29 |
| Support Level | $0.71 | $1.11 |
| Resistance Level | $1.25 | $2.08 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 44.06 | 31.37 |
First Breach Inc is an American defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing unmanned aerial systems for commercial, law enforcement, and military markets. Its ammunition operations include the in-house production of brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition. The company is also developing U.S.-made unmanned aerial systems incorporating robotics, intelligence, surveillance and reconnaissance (ISR), sensor, and precision manufacturing technologies for defense, homeland security, law enforcement, and commercial applications.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.